# Assessing Virologic Success and Metabolic Changes in Patients Switching From a TDF to TAF Containing Antiretroviral Therapy Regimen

> **NCT03646370** · — · COMPLETED · sponsor: **Thomas Jefferson University** · enrollment: 110 (actual)

## Conditions studied

- HIV-1-infection
- Metabolic Syndrome
- Cardiovascular Diseases
- Weight Gain
- Renal Function Abnormal
- Hyperglycemia

## Interventions

- **DRUG:** Tenofovir Alafenamide

## Key facts

- **NCT ID:** NCT03646370
- **Lead sponsor:** Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-25
- **Primary completion:** 2019-07-24
- **Final completion:** 2019-07-24
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2019-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03646370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03646370, "Assessing Virologic Success and Metabolic Changes in Patients Switching From a TDF to TAF Containing Antiretroviral Therapy Regimen". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03646370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*